Loading
Life sciences · Journal article
International Journal of Nanomedicine · September 1, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of nanotechnology-enhanced flavonoid delivery systems, synthesizing literature from 2015–2025 across multiple nanocarrier platforms (polymeric, lipid, metallic, and others). The review documents preclinical improvements in flavonoid solubility, bioavailability, stability, and targeted delivery, but explicitly identifies the absence of rigorous clinical trials and standardized protocols as barriers to clinical translation.
Narrative review of literature.
Nanosystems have demonstrated improvements in flavonoids' solubility, cellular uptake, circulation time, and stability in preclinical studies Nanotechnology-enhanced delivery facilitates targeted and sustained release to sites of infection and inflammation Green synthetic approaches for flavonoids and their formulations enhance safety, reduce toxicity, and improve stability
Green synthetic approaches for flavonoids and their formulations enhance safety, reduce toxicity, and improve stability Clinical translation is not yet achieved; requires standardized sources, reproducible protocols, comprehensive characterization, toxicity evaluations, and rigorously designed clinical trials
Clinicians should recognize that while flavonoid nanoformulations show promising preclinical antimicrobial and antiviral activity, no clinical evidence currently supports their use in patient care; translation requires standardized development, toxicity assessment, and rigorous controlled trials before clinical adoption.
This is a narrative review synthesizing preclinical evidence on nanotechnology-enhanced flavonoid delivery; it raises mechanistic and translational questions rather than reporting original clinical or rigorous experimental data to answer them.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that while flavonoid nanoformulations show promising preclinical antimicrobial and antiviral activity, no clinical evidence currently supports their use in patient care; translation requires standardized development, toxicity assessment, and rigorous controlled trials before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract: Flavonoids are a class of naturally occurring compounds primarily present in plants and are also part of some of the byproducts of certain insects’ metabolites, such as propolis. Given the growing burden of infectious diseases and the urgent need for more effective therapeutic options, advancing flavonoid-based interventions is of prime clinical significance. These compounds possess unique chemical characteristics and exhibit pronounced biological activities, including antioxidant, anti-inflammatory, antiviral, immunomodulatory, and antibacterial, making the class a potent contender for managing certain health concerns, including health issues arising out of pandemic situations. However, limitations involving low aqueous solubility, less oral bioavailability, fast metabolism, structural instability, and limited tissue targeting have restricted their clinical applications as therapeutic agents. In this context, nanotechnology offers feasible remediation to overcome these shortcomings by enhancing solubility, absorption, transitional stability, and controlled and sustained release, as well as enhanced on-site bioavailability and effective therapeutic control that transforms into increased biological activity. The current overview encompasses literature information collected from the database platforms of PubMed, Google Scholar, ScienceDirect, Scopus, and Web of Science, with the particular focus on studies published in the last decade (2015– 2025). Information relating to nanotechnology-enabled flavonoid delivery covering polymeric and lipid nanoencapsulates, nanoemulsions, nanocrystals, liposomes, solid lipid nanoparticles (SLNPs), nanostructured lipid carriers, metallic NPs, and nanofibers has been assessed and analyzed. These nanosystems and complex delivery platforms have demonstrated improvements in flavonoids’ solubility, cellular uptake, circulation time, and stability and have facilitated targeted/sustained release of the payload to the sites of action, ie, infections and inflammations. Additionally, the environmentally benign green synthetic approaches for constituent flavonoids and their formulations emphasized the roles in enhancing the safety, toxicity reduction, stability, and sustainable use. Although preclinical studies have produced encouraging therapeutic results, the clinical translation requires standardized flavonoid sources, reproducible protocols, scaling-up formulation methods, comprehensive physicochemical characterization, toxicity evaluations, and pharmacokinetic studies with rigorously designed clinical trials. Keywords: flavonoids, nanotechnology, nanocarriers, antimicrobial, antiviral, preclinical, drug delivery
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.